SGLT-2 Inhibitors
SGLT-2 inhibitors are a type of oral medication that people with type 2 diabetes can use to lower blood sugar levels.
How do SGLT-2 inhibitors work to lower blood sugar
As our kidneys filter our blood, they also reabsorb glucose. SGLT-2 inhibitor drugs block the process of reabsorbing glucose back into our blood, causing glucose to be excreted through urine. Since extra glucose leaves the body instead of returning to the bloodstream, SGLT-2 inhibitors can lower the amount of sugar in the blood and, as a result, they can also lower A1C levels and body weight.
List of SGLT-2 inhibitor medications
Commonly medications in the SGLT-2 drug class include:
Frequently Asked Questions About SGLT-2 Inhibitors
Further reading about SGLT-2 inhibitor medications
SGLT-2s and their cardiovascular and kidney benefits
- Farxiga Shows Potential to Protect Millions of People with Chronic Kidney Disease
- Medications That Protect the Heart: New Data on SGLT-2s and GLP-1s
- Studies Suggest Diabetes Drugs Help Hearts and Kidneys for People With or Without Diabetes
- Great News: Trials Show Some Diabetes Drugs Can Actually Protect Your Kidneys
- What are SGLT-2 Inhibitors and How Can They Help Your Heart
- Invokana: Heart & Kidney Benefits, Same Safety Concerns on Amputation
- Jardiance: The First Diabetes Drug to Reduce Risk of Heart-Related Death
- SGLT-2 Inhibitor Jardiance Reduces Cardiovascular Events by 14% in High-Risk
Taking SGLT-2 medications with type 1 diabetes
Latest Articles About Insulin
See All SGLT-2 Inhibitors News
Top Diabetes Drugs Anticipated To Get Lower Medicare Pricing
Since the passage of the Inflation Reduction Act in 2022, the federal government has been able to negotiate the prices it pays for high-cost prescription drugs covered under Medicare. Lower prices for 15 medications – including Ozempic, Wegovy, and Rybelsus – have been negotiated for 2027 as part of ongoing Medicare drug price negotiations.
Trial Tests New Drug Combo To Reduce Cardiovascular Risk in Type 2
If you have type 2 diabetes, high blood pressure, and cardiovascular disease without a history of heart failure, you may be eligible for a clinical trial testing whether a new investigational drug taken with Jardiance can reduce the risk of heart-related issues.
Brenzavvy, a Type 2 Diabetes Drug, Available for Less Than $50 Month
Key takeaways: * A relatively newer drug on the U.S. market, Brenzavvy is a lower-priced type 2 diabetes drug approved in 2023. Unlike other SGLT-2 inhibitors, many of which cost hundreds of dollars per month without insurance, Brenzavvy is only $50 per month through Cost Plus Drugs. * Brenzavvy is an SGLT-2 inhibitor that helps lower blood sugar in people with type 2 diabetes and provides additional benefits like weight loss, blood pressure reduction, and kidney and heart protection. * Until recently, Brenzavvy was only available through online pharmacies like Cost Plus Drugs, but it is now being offered at Publix pharmacies.
Diabetes Drugs Show Promise for Reducing Dementia Risk
Key takeaways: * People with type 2 diabetes who took SGLT-2 inhibitors saw significantly lower rates of dementia and Parkinson's disease. * Studies have shown that other diabetes drugs, including metformin and GLP-1 agonists, may reduce the risk of dementia. * Researchers suggest that these drugs appear to have benefits that go beyond lowering blood sugar levels.